MA33503B1 - L-asparaginase pegylée - Google Patents
L-asparaginase pegyléeInfo
- Publication number
- MA33503B1 MA33503B1 MA34598A MA34598A MA33503B1 MA 33503 B1 MA33503 B1 MA 33503B1 MA 34598 A MA34598 A MA 34598A MA 34598 A MA34598 A MA 34598A MA 33503 B1 MA33503 B1 MA 33503B1
- Authority
- MA
- Morocco
- Prior art keywords
- conjugate
- relates
- asparaginase
- protein
- polyethylene glycol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
- C12N9/82—Asparaginase (3.5.1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01001—Asparaginase (3.5.1.1)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22332009P | 2009-07-06 | 2009-07-06 | |
| PCT/EP2010/054156 WO2011003633A1 (en) | 2009-07-06 | 2010-03-30 | Pegylated l-asparaginase |
| PCT/EP2010/059599 WO2011003886A1 (en) | 2009-07-06 | 2010-07-06 | Pegylated l-asparaginase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA33503B1 true MA33503B1 (fr) | 2012-08-01 |
Family
ID=42232655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA34598A MA33503B1 (fr) | 2009-07-06 | 2010-07-06 | L-asparaginase pegylée |
Country Status (25)
| Country | Link |
|---|---|
| US (6) | US20120100121A1 (enExample) |
| JP (1) | JP6014956B2 (enExample) |
| KR (1) | KR101731999B1 (enExample) |
| CN (1) | CN102573917B (enExample) |
| AU (1) | AU2010270294B2 (enExample) |
| BR (1) | BR112012000367A2 (enExample) |
| CA (1) | CA2767149C (enExample) |
| CO (1) | CO6612174A2 (enExample) |
| DK (1) | DK2451486T4 (enExample) |
| EA (1) | EA021168B1 (enExample) |
| ES (1) | ES2636476T5 (enExample) |
| FI (1) | FI2451486T4 (enExample) |
| HU (1) | HUE035771T2 (enExample) |
| IL (1) | IL217392A (enExample) |
| IN (1) | IN2012DN00958A (enExample) |
| LT (1) | LT2451486T (enExample) |
| MA (1) | MA33503B1 (enExample) |
| MX (1) | MX2012000424A (enExample) |
| MY (1) | MY180758A (enExample) |
| NZ (1) | NZ597912A (enExample) |
| PE (2) | PE20120501A1 (enExample) |
| PT (1) | PT2451486T (enExample) |
| SG (1) | SG176984A1 (enExample) |
| UA (1) | UA104634C2 (enExample) |
| WO (2) | WO2011003633A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE531779C2 (sv) * | 2007-11-26 | 2009-08-04 | Promimic Ab | Framställning av kalciumfosfatpartiklar i nanostorlek som pulver eller beläggning via bifunktionella prekursorer |
| WO2011003633A1 (en) | 2009-07-06 | 2011-01-13 | Alize Pharma Ii | Pegylated l-asparaginase |
| WO2015033344A1 (en) | 2013-09-05 | 2015-03-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs) |
| WO2015038639A1 (en) * | 2013-09-10 | 2015-03-19 | Sandia Corporation | Therapeutic asparaginases |
| CN104046600B (zh) | 2013-12-30 | 2019-04-05 | 江苏众红生物工程创药研究院有限公司 | 多臂聚乙二醇修饰剂的新用途及其在修饰门冬酰胺酶中的应用 |
| BR102014000585B1 (pt) | 2014-01-10 | 2021-01-12 | Coppe/Ufrj-Instituto Alberto Luiz Coimbra De Pós-Graduação | l-asparaginase recombinante de zymomonas |
| US9808011B2 (en) | 2014-12-15 | 2017-11-07 | Biovectra Inc. | Pentacyclic triterpene compounds and uses thereof |
| CN105802948B (zh) | 2014-12-29 | 2020-06-09 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇定点修饰的门冬酰胺酶及其制备方法与应用 |
| ES2839212T3 (es) | 2015-09-29 | 2021-07-05 | Inst Nat Sante Rech Med | Métodos para determinar el estado metabólico de linfomas B |
| US10821160B2 (en) | 2016-03-01 | 2020-11-03 | The Board Of Trustees Of The University Of Illinois | L-asparaginase variants and fusion proteins with reduced L-glutaminase activity and enhanced stability |
| HRP20212027T1 (hr) * | 2016-06-01 | 2022-04-01 | Servier IP UK Limited | Formulacije polialkilen oksidne asparaginaze i postupci njihove priprave i uporabe |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| WO2018085493A1 (en) * | 2016-11-04 | 2018-05-11 | Georgia State University Research Foundation, Inc. | Endotoxin free asparaginase |
| US10174302B1 (en) | 2017-06-21 | 2019-01-08 | Xl-Protein Gmbh | Modified L-asparaginase |
| EP3418383A1 (en) * | 2017-06-21 | 2018-12-26 | XL-protein GmbH | Modified l-asparaginase |
| CN111315878B (zh) * | 2017-06-21 | 2024-04-26 | 爵士制药爱尔兰有限公司 | 经修饰l-天冬酰胺酶 |
| WO2019083793A1 (en) * | 2017-10-27 | 2019-05-02 | Pfenex Inc. | Method for production of recombinant erwinia asparaginase |
| CN111278979B (zh) | 2017-10-27 | 2024-05-31 | 佩利肯科技控股公司 | 重组大肠杆菌天冬酰胺酶的生产方法 |
| KR20250086810A (ko) * | 2017-11-30 | 2025-06-13 | 재즈 파마슈티칼즈 아일랜드 리미티드 | 아스파라기나제를 이용한 치료 방법 |
| JP2021520828A (ja) * | 2018-04-19 | 2021-08-26 | キンドレッド バイオサイエンシズ インコーポレイテッド | 医療用の変異体アスパラギナーゼポリペプチド |
| US20210299233A1 (en) | 2018-07-12 | 2021-09-30 | The Children's Medical Center Corporation | Method for treating cancer |
| EP3867369A4 (en) * | 2018-12-24 | 2022-09-14 | Gennova Biopharmaceuticals Limited | FREEZE-DRIED COMPOSITION OF PEGASPARGASE |
| WO2020178695A1 (en) | 2019-03-01 | 2020-09-10 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| GB201912020D0 (en) * | 2019-08-21 | 2019-10-02 | Porton Biopharma Ltd | Therapeutic Conjugate |
| JP2022553399A (ja) * | 2019-10-25 | 2022-12-22 | ジャズ ファーマシューティカルズ アイルランド リミテッド | 組換えｌ－アスパラギナーゼ |
| KR102269634B1 (ko) * | 2019-10-31 | 2021-06-25 | 대상 주식회사 | ansB 유전자 불활성화에 의해 아미노산 생산능력이 향상된 균주 |
| MX2023007516A (es) | 2020-12-23 | 2023-09-14 | Jazz Pharmaceuticals Ireland Ltd | Metodos de purificacion de proteinas de fusion con proteccion de carga. |
| CN114854729B (zh) * | 2021-02-03 | 2025-09-02 | 重庆派金生物科技有限公司 | 定向化学偶联门冬酰胺酶突变体及其制备方法和应用 |
| WO2022211829A1 (en) | 2021-03-30 | 2022-10-06 | Jazz Pharmaceuticals Ireland Ltd. | Dosing of recombinant l-asparaginase |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| EP4551216A1 (en) | 2022-07-04 | 2025-05-14 | Institut National de la Santé et de la Recherche Médicale | Use of a l-asparaginase in combination with a ferroptosis inducer for the treatment of extranodal natural killer/t-cell lymphoma |
| WO2024015529A2 (en) | 2022-07-14 | 2024-01-18 | Jazz Pharmaceuticals Ireland Ltd. | Combination therapies involving l-asparaginase |
| WO2024211977A1 (pt) * | 2023-04-12 | 2024-10-17 | Biobreyer Pesquisa E Desenvolvimento Científico Ltda | Processo de peguilação sítio específica de lasparaginase contendo cisteínas de superfície, produto obtido por processo e uso |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US5286637A (en) | 1989-08-07 | 1994-02-15 | Debiopharm, S.A. | Biologically active drug polymer derivatives and method for preparing same |
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| GB9017002D0 (en) * | 1990-08-02 | 1990-09-19 | Health Lab Service Board | Improved method for the purification of erwina l-asparaginase |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| US5776746A (en) | 1996-05-01 | 1998-07-07 | Genitope Corporation | Gene amplification methods |
| US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| US20020065397A1 (en) | 2000-10-12 | 2002-05-30 | Joseph Roberts | Protecting therapeutic compositions from host-mediated inactivation |
| US6913915B2 (en) * | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
| AU2002332371A1 (en) * | 2001-08-22 | 2003-03-10 | Gosudarstvennoe Uchrezhdenie Nauchno-Issledovatelsky Institut Biomeditsinskoy Khimii Im. Orekhovicha | Recombinant l-asparaginase less thanigreater thanerwinia caratovoraless than/igreater than |
| CN102212019B (zh) | 2003-03-14 | 2015-05-27 | 蔚所番有限公司 | 支化水溶性聚合物及其缀合物 |
| WO2007103290A2 (en) | 2006-03-03 | 2007-09-13 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Materials and methods directed to asparagine synthetase and asparaginase therapies |
| EP2011639A4 (en) | 2006-04-21 | 2012-03-07 | Konica Minolta Holdings Inc | GASSPERRFILM, HARZBASIS FOR ELECTROLUMINESCENCE DEVICE, THIS USING ELECTROLUMINESCENCE DEVICE AND METHOD FOR PRODUCING A GASPERRFILM |
| DK2137307T3 (da) * | 2007-03-09 | 2014-11-03 | Novozymes As | Termostabile asparaginaser |
| WO2011003633A1 (en) | 2009-07-06 | 2011-01-13 | Alize Pharma Ii | Pegylated l-asparaginase |
| EP3389720A1 (en) | 2015-12-18 | 2018-10-24 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
-
2010
- 2010-03-30 WO PCT/EP2010/054156 patent/WO2011003633A1/en not_active Ceased
- 2010-07-06 EA EA201270134A patent/EA021168B1/ru not_active IP Right Cessation
- 2010-07-06 BR BR112012000367A patent/BR112012000367A2/pt not_active Application Discontinuation
- 2010-07-06 ES ES10730170T patent/ES2636476T5/es active Active
- 2010-07-06 AU AU2010270294A patent/AU2010270294B2/en active Active
- 2010-07-06 DK DK10730170.7T patent/DK2451486T4/da active
- 2010-07-06 CN CN201080030392.6A patent/CN102573917B/zh active Active
- 2010-07-06 MY MYPI2012000054A patent/MY180758A/en unknown
- 2010-07-06 US US13/382,276 patent/US20120100121A1/en not_active Abandoned
- 2010-07-06 UA UAA201201135A patent/UA104634C2/ru unknown
- 2010-07-06 MA MA34598A patent/MA33503B1/fr unknown
- 2010-07-06 FI FIEP10730170.7T patent/FI2451486T4/fi active
- 2010-07-06 LT LTEP10730170.7T patent/LT2451486T/lt unknown
- 2010-07-06 PT PT107301707T patent/PT2451486T/pt unknown
- 2010-07-06 KR KR1020127003202A patent/KR101731999B1/ko active Active
- 2010-07-06 HU HUE10730170A patent/HUE035771T2/en unknown
- 2010-07-06 PE PE2012000023A patent/PE20120501A1/es not_active Application Discontinuation
- 2010-07-06 MX MX2012000424A patent/MX2012000424A/es active IP Right Grant
- 2010-07-06 JP JP2012518956A patent/JP6014956B2/ja active Active
- 2010-07-06 CA CA2767149A patent/CA2767149C/en active Active
- 2010-07-06 NZ NZ597912A patent/NZ597912A/en unknown
- 2010-07-06 WO PCT/EP2010/059599 patent/WO2011003886A1/en not_active Ceased
- 2010-07-06 SG SG2011096013A patent/SG176984A1/en unknown
- 2010-07-06 PE PE2016001555A patent/PE20161325A1/es unknown
-
2012
- 2012-01-05 IL IL217392A patent/IL217392A/en active IP Right Grant
- 2012-02-02 IN IN958DEN2012 patent/IN2012DN00958A/en unknown
- 2012-02-06 CO CO12020409A patent/CO6612174A2/es unknown
-
2015
- 2015-08-05 US US14/819,305 patent/US9920311B2/en not_active Ceased
-
2018
- 2018-02-01 US US15/886,216 patent/US20180346900A1/en not_active Abandoned
-
2020
- 2020-03-18 US US16/822,764 patent/USRE49736E1/en active Active
- 2020-05-18 US US16/877,324 patent/US11046946B2/en active Active
-
2021
- 2021-06-03 US US17/338,508 patent/US12441992B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA33503B1 (fr) | L-asparaginase pegylée | |
| Winkler et al. | Hematopoietic stem cell mobilizing agents G-CSF, cyclophosphamide or AMD3100 have distinct mechanisms of action on bone marrow HSC niches and bone formation | |
| JP6884155B2 (ja) | 癌治療のための併用免疫療法及びサイトカイン制御療法 | |
| Liu et al. | LncRNA-targeting bio-scaffold mediates triple immune effects for postoperative colorectal cancer immunotherapy | |
| JP6633056B2 (ja) | 移植片対宿主病（ｇｖｈｄ）または表皮水疱症（ｅｂ）のエキソソームによる治療方法 | |
| TWI322184B (en) | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates | |
| AU2025201558A1 (en) | Compositions and methods for treating diseases and disorders of the central nervous system | |
| AU2021204332A1 (en) | Placenta-derived adherent cell exosomes and uses thereof | |
| JP2012532185A5 (enExample) | ||
| CN113106053A (zh) | 治疗性汇集的血液凋亡细胞制剂与其用途 | |
| Che et al. | Lymph‐node‐targeted drug delivery for effective immunomodulation to prolong the long‐term survival after heart transplantation | |
| KR20170131562A (ko) | 암 약물과의 조합 요법에서의 nk-92 세포 | |
| US9610331B2 (en) | Methods for hematopoietic precursor mobilization | |
| Cramer et al. | Mobilization of hematopoietic progenitor cells by yeast-derived β-glucan requires activation of matrix metalloproteinase-9 | |
| US20220054610A1 (en) | Slow-cycling cell-rna based nanoparticle vaccine to treat cancer | |
| Black et al. | Analysis of Propionibacterium amis‐induced non‐specific immunity to Trypanosoma brucei in mice | |
| JP7412576B2 (ja) | 腎がんの相乗的治療におけるペグインターフェロンおよびプロトオンコジーン産物標的阻害剤の適用 | |
| JP7076103B2 (ja) | 中枢神経腫瘍の処置 | |
| WO2022056117A1 (en) | Nucleic acid-polypeptide compositions and uses thereof | |
| Itoh et al. | Sulfasalazine, a potent cystine-glutamate transporter inhibitor, enhances osteogenic differentiation of canine adipose-derived stem cells | |
| Serack | Development of a Cell-based Regenerative Strategy to Modulate Angiogenesis and Inflammation in Ischemic Muscle | |
| Berrada et al. | Real-world efficacy and toxicity of the LMBA02 protocol for Burkitt lymphoma in Morocco | |
| Yan et al. | Folate-modified biomimetic nanovesicles loaded with a PU. 1 inhibitor alleviate atherosclerosis by suppressing inflammation | |
| WO2024192172A1 (en) | Dendritic cell populations that inhibit gvhd | |
| TH149173A (th) | L-แอสพาราจิเนสที่ถูกเติม peg |